drugset / Trial / NCT00348023

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

NCT00348023

Phase 4 Completed Innovative Medical
RandomizedParallel-groupSingle-blind

Summary

Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified 0.03 %
Subject Timolol Other / unclassified 0.5 %
Subject Travoprost Other / unclassified 0.004 %

Indications